Last reviewed · How we verify
Nicotine Polacrilex Gum (2 mg)
Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine binds to nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid.
At a glance
| Generic name | Nicotine Polacrilex Gum (2 mg) |
|---|---|
| Sponsor | University of Hawaii |
| Drug class | Nicotine replacement therapy |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Nicotine polacrilex is a nicotine replacement therapy in which nicotine is bound to an ion-exchange resin (polacrilex) and delivered via chewing gum. When chewed, nicotine is released and absorbed through the oral mucosa, binding to nicotinic acetylcholine receptors throughout the central and peripheral nervous system. This activation mimics the effects of smoking without the harmful combustion byproducts, thereby reducing withdrawal symptoms and cravings that occur during smoking cessation attempts.
Approved indications
- Smoking cessation aid
- Reduction of nicotine withdrawal symptoms
Common side effects
- Mouth and throat irritation
- Hiccups
- Dyspepsia
- Jaw soreness
- Nausea
- Headache
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders (PHASE3)
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Abuse Liability for Five Modern Oral Nicotine Products (NA)
- Effects of Caffeine and Nicotine Gum on Balance Performance in Athletes (NA)
- Quit-Smoking Study for Native Hawaiians (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine Polacrilex Gum (2 mg) CI brief — competitive landscape report
- Nicotine Polacrilex Gum (2 mg) updates RSS · CI watch RSS
- University of Hawaii portfolio CI